Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 401 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Terminally Ill ‘Flamingo Lady’ Gets Emotional After Dying Wish Comes True September 27, 2021 Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in... August 11, 2026 Celebrate with Us! Vaccine Rollouts Mark the Light at the End... March 8, 2021 As Winter Storms Plague Southern States, GreaterGood Is Helping Where It’s... February 25, 2021 Load more HOT NEWS New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations... What Cancer Caregivers Should Know About Hospice Care at Home: A... 2026 ESMO TAT Honorary Award Recipient Announced Breast Cancer Patient Does Head-Shaving Photo Shoot in Hopes of Inspiring...
